

# Robert L Ali

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8572464/publications.pdf>

Version: 2024-02-01

164  
papers

9,653  
citations

71102

41  
h-index

43889

91  
g-index

166  
all docs

166  
docs citations

166  
times ranked

9323  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility. <i>Addiction</i> , 2002, 97, 1183-1194.	3.3	1,344
2	Validation of the alcohol, smoking and substance involvement screening test (ASSIST). <i>Addiction</i> , 2008, 103, 1039-1047.	3.3	825
3	Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. <i>Addiction</i> , 2018, 113, 1905-1926.	3.3	685
4	Global statistics on addictive behaviours: 2014 status report. <i>Addiction</i> , 2015, 110, 904-919.	3.3	311
5	Hyperalgesic responses in methadone maintenance patients. <i>Pain</i> , 2001, 90, 91-96.	4.2	272
6	Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. <i>Addiction</i> , 2003, 98, 441-452.	3.3	246
7	Validation of the World Health Organization Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): report of results from the Australian site. <i>Drug and Alcohol Review</i> , 2005, 24, 217-226.	2.1	220
8	The characteristics of heroin users entering treatment: findings from the Australian Treatment Outcome Study (ATOS). <i>Drug and Alcohol Review</i> , 2005, 24, 411-418.	2.1	204
9	Oral substitution treatment of injecting opioid users for prevention of HIV infection. <i>The Cochrane Library</i> , 2011, , CD004145.	2.8	197
10	Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS. <i>Addiction</i> , 2008, 103, 1484-1492.	3.3	192
11	Experience of non-fatal overdose among heroin users in Adelaide, Australia: circumstances and risk perceptions. <i>Addiction</i> , 1998, 93, 701-711.	3.3	175
12	Dose-Related Psychotic Symptoms in Chronic Methamphetamine Users. <i>JAMA Psychiatry</i> , 2013, 70, 319.	11.0	170
13	Responding to global stimulant use: challenges and opportunities. <i>Lancet</i> , 2019, 394, 1652-1667.	13.7	169
14	A randomized controlled trial of a brief intervention for illicit drugs linked to the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) in clients recruited from primary health care settings in four countries. <i>Addiction</i> , 2012, 107, 957-966.	3.3	167
15	Psychotic symptoms in methamphetamine psychotic in-patients. <i>International Journal of Neuropsychopharmacology</i> , 2003, 6, 347-352.	2.1	164
16	Exposure to opioid maintenance treatment reduces long-term mortality. <i>Addiction</i> , 2008, 103, 462-468.	3.3	161
17	A review of biological indicators of illicit drug use, practical considerations and clinical usefulness. <i>Addiction</i> , 1999, 94, 1279-1298.	3.3	154
18	The rise of methamphetamine in Southeast and East Asia. <i>Drug and Alcohol Review</i> , 2008, 27, 220-228.	2.1	128

#	ARTICLE	IF	CITATIONS
19	The health effects of ecstasy: a literature review. Drug and Alcohol Review, 2002, 21, 53-63.	2.1	126
20	Buprenorphine for the management of opioid withdrawal. , 2009, , CD002025.		124
21	Alpha<sub>2</sub>-adrenergic agonists for the management of opioid withdrawal. The Cochrane Library, 2016, 2016, CD002024.	2.8	122
22	One year outcomes for heroin dependence: Findings from the Australian Treatment Outcome Study (ATOS). Drug and Alcohol Dependence, 2006, 83, 174-180.	3.2	118
23	Evaluating the impact of community-based treatment options on methamphetamine use: findings from the <sc>M</sc>ethamphetamine <sc>T</sc>reatment <sc>E</sc>valuation <sc>S</sc>tudy (<sc>MATES</sc>). Addiction, 2012, 107, 1998-2008.	3.3	108
24	Methamphetamine: drug use and psychoses becomes a major public health issue in the Asia Pacific region. Addiction, 2002, 97, 771-772.	3.3	101
25	Buprenorphine versus methadone maintenance: a cost-effectiveness analysis. Drug and Alcohol Dependence, 2003, 71, 295-302.	3.2	101
26	Substitution treatment of injecting opioid users for prevention of HIV infection. , 2008, , CD004145.		98
27	Ultra-rapid screening for substance-use disorders: The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST-Lite). Drug and Alcohol Dependence, 2013, 132, 352-361.	3.2	95
28	Pharmacotherapies for cannabis dependence. The Cochrane Library, 2014, , CD008940.	2.8	94
29	Methadone at tapered doses for the management of opioid withdrawal. The Cochrane Library, 2013, , CD003409.	2.8	92
30	Comparisons of methamphetamine psychotic and schizophrenic symptoms: A differential item functioning analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 959-964.	4.8	77
31	Factors associated with 12 months continuous heroin abstinence: findings from the Australian Treatment Outcome Study (ATOS). Journal of Substance Abuse Treatment, 2005, 28, 255-263.	2.8	76
32	The Impact of Cannabis Decriminalisation in Australia and the United States. Journal of Public Health Policy, 2000, 21, 157.	2.0	71
33	HIV prevalence and risk behaviour in needle exchange attenders: a national study. Medical Journal of Australia, 1997, 166, 237-240.	1.7	68
34	Buprenorphine for managing opioid withdrawal. The Cochrane Library, 2017, 2017, CD002025.	2.8	66
35	BRIEF REPORT: Methadone Treatment of Injecting Opioid Users for Prevention of HIV Infection. Journal of General Internal Medicine, 2006, 21, 193-195.	2.6	66
36	<b>α</b>-Adrenergic agonists in opioid withdrawal. Addiction, 2002, 97, 49-58.	3.3	63

#	ARTICLE	IF	CITATIONS
37	Post-marketing surveillance of buprenorphine-naloxone in Australia: Diversion, injection and adherence with supervised dosing. <i>Drug and Alcohol Dependence</i> , 2011, 118, 265-273.	3.2	62
38	Methadone at tapered doses for the management of opioid withdrawal. , 2005, , CD003409.		56
39	Effectiveness of drug dependence treatment in HIV prevention. <i>International Journal of Drug Policy</i> , 2005, 16, 67-75.	3.3	55
40	Buprenorphine for the management of opioid withdrawal. , 2006, , CD002025.		55
41	Predictive factors for treatment retention in methadone programs in Indonesia. <i>Journal of Substance Abuse Treatment</i> , 2012, 42, 239-246.	2.8	52
42	Bloody needles. <i>Aids</i> , 1991, 5, 1025-1028.	2.2	50
43	Global opioid agonist treatment: a review of clinical practices by country. <i>Addiction</i> , 2020, 115, 2243-2254.	3.3	50
44	Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia. <i>Addiction</i> , 2020, 115, 1295-1305.	3.3	46
45	Measurement-based care using DSM-5 for opioid use disorder: can we make opioid medication treatment more effective?. <i>Addiction</i> , 2019, 114, 1346-1353.	3.3	45
46	Alpha <sub>2</sub> -adrenergic agonists for the management of opioid withdrawal. , 2014, , CD002024.		44
47	The diversion and injection of a buprenorphine-naloxone soluble film formulation. <i>Drug and Alcohol Dependence</i> , 2014, 136, 21-27.	3.2	43
48	Pharmacogenomics of methadone maintenance treatment. <i>Pharmacogenomics</i> , 2014, 15, 1007-1027.	1.3	43
49	Drug policy in Vietnam: A decade of change?. <i>International Journal of Drug Policy</i> , 2012, 23, 319-326.	3.3	42
50	A comparison of antagonist-precipitated withdrawal under anesthesia to standard inpatient withdrawal as a precursor to maintenance naltrexone treatment in heroin users: outcomes at 6 and 12 months. <i>Drug and Alcohol Dependence</i> , 2002, 68, 5-14.	3.2	41
51	Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. <i>The Cochrane Library</i> , 2010, , CD002022.	2.8	41
52	Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation. <i>Medical Journal of Australia</i> , 2009, 191, 161-165.	1.7	40
53	Alpha <sub>2</sub> -adrenergic agonists for the management of opioid withdrawal. , 2009, , CD002024.		39
54	A randomised controlled trial of sublingual buprenorphine-naloxone film versus tablets in the management of opioid dependence. <i>Drug and Alcohol Dependence</i> , 2013, 131, 119-126.	3.2	39

#	ARTICLE	IF	CITATIONS
55	Heroin users in Australia: population trends. <i>Drug and Alcohol Review</i> , 2004, 23, 107-116.	2.1	35
56	Pregnancy-related changes in tobacco, alcohol and cannabis use reported by antenatal patients at two public hospitals in South Australia. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2008, 48, 248-254.	1.0	35
57	Opioid antagonists with minimal sedation for opioid withdrawal. <i>The Cochrane Library</i> , 2017, 2017, CD002021.	2.8	35
58	HIV prevalence and risk behaviours for HIV transmission in South Australian prisons. <i>Aids</i> , 1991, 5, 845-852.	2.2	34
59	Physical and mental health problems in amphetamine users from metropolitan Adelaide, Australia. <i>Drug and Alcohol Review</i> , 1998, 17, 187-195.	2.1	33
60	Prevalence and correlates of intravenous methadone syrup administration in Adelaide, Australia. <i>Addiction</i> , 2003, 98, 413-418.	3.3	33
61	Using routinely collected data to understand and predict adverse outcomes in opioid agonist treatment: Protocol for the Opioid Agonist Treatment Safety (OATS) Study. <i>BMJ Open</i> , 2018, 8, e025204.	1.9	31
62	The introduction of a potentially abuse deterrent oxycodone formulation: Early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study. <i>Drug and Alcohol Dependence</i> , 2015, 151, 56-67.	3.2	29
63	Facilitating a transition from compulsory detention of people who use drugs towards voluntary community-based drug dependence treatment and support services in Asia. <i>Harm Reduction Journal</i> , 2015, 12, 31.	3.2	28
64	Correlates of transient versus persistent psychotic symptoms among dependent methamphetamine users. <i>Psychiatry Research</i> , 2016, 238, 166-171.	3.3	28
65	The effect of a potentially tamper-resistant oxycodone formulation on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study. <i>Lancet Psychiatry</i> , 2018, 5, 155-166.	7.4	28
66	The place of detoxification in treatment of opioid dependence. <i>Current Opinion in Psychiatry</i> , 2006, 19, 266-270.	6.3	27
67	Opioid antagonists with minimal sedation for opioid withdrawal. , 2009, , CD002021.		27
68	Cochrane systematic reviews in the field of addiction: What's there and what should be. <i>Drug and Alcohol Dependence</i> , 2011, 113, 96-103.	3.2	26
69	Relationship between LAAM methadone preference and treatment outcomes. <i>Drug and Alcohol Dependence</i> , 2002, 66, 295-301.	3.2	23
70	Impact of the heroin "drought" on patterns of drug use and drug-related harms. <i>Drug and Alcohol Review</i> , 2004, 23, 143-150.	2.1	23
71	Short-term outcomes of five heroin detoxification methods in the Australian NEPOD Project. <i>Addictive Behaviors</i> , 2005, 30, 443-456.	3.0	23
72	Short-term Outcomes for the Treatment of Heroin Dependence. <i>Addictive Disorders and Their Treatment</i> , 2006, 5, 133-143.	0.5	23

#	ARTICLE	IF	CITATIONS
73	Development of the Addiction Dimensions for Assessment and Personalised Treatment (ADAPT). Drug and Alcohol Dependence, 2014, 139, 121-131.	3.2	22
74	Cost-effectiveness of center-based compulsory rehabilitation compared to community-based voluntary methadone maintenance treatment in Hai Phong City, Vietnam. Drug and Alcohol Dependence, 2016, 168, 147-155.	3.2	22
75	Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence. International Journal of Drug Policy, 2022, 100, 103492.	3.3	22
76	A cost-effectiveness analysis of heroin detoxification methods in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addictive Behaviors, 2006, 31, 371-387.	3.0	21
77	Prescribers' perceptions of the diversion and injection of medication by opioid substitution treatment patients. Drug and Alcohol Review, 2011, 30, 613-620.	2.1	21
78	The extramedical use and diversion of opioid substitution medications and other medications in prison settings in Australia following the introduction of buprenorphine/naloxone film. Drug and Alcohol Review, 2016, 35, 76-82.	2.1	21
79	The characteristics of a cohort who tamper with prescribed and diverted opioid medications. Journal of Substance Abuse Treatment, 2015, 58, 51-61.	2.8	20
80	Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol. Addiction, 2015, 110, 226-237.	3.3	19
81	Improvements in retention rates and changes in client group with methadone maintenance streaming. Drug and Alcohol Review, 1996, 15, 83-88.	2.1	18
82	Characteristics of amphetamine users seeking information, help and treatment in Adelaide, South Australia. Drug and Alcohol Review, 1999, 18, 63-73.	2.1	18
83	Accidental Fatalities Among Heroin Users in South Australia, 1994-1997: Toxicological Findings and Circumstances of Death. Addiction Research and Theory, 2002, 10, 335-346.	1.9	18
84	Alpha2 adrenergic agonists for the management of opioid withdrawal. , 2004, , CD002024.		18
85	The political and scientific challenges in evaluating compulsory drug treatment centers in Southeast Asia. Harm Reduction Journal, 2017, 14, 2.	3.2	18
86	Transferring Patients From Methadone to Buprenorphine: The Feasibility and Evaluation of Practice Guidelines. Journal of Addiction Medicine, 2018, 12, 234-240.	2.6	18
87	Comparison of tincture of opium and methadone to control opioid withdrawal in a Thai treatment centre. British Journal of Clinical Pharmacology, 2004, 58, 536-541.	2.4	17
88	Flexible dosing of Tincture of Opium in the management of opioid withdrawal: pharmacokinetics and pharmacodynamics. British Journal of Clinical Pharmacology, 2008, 66, 640-7.	2.4	17
89	United Nations Office on Drugs and Crime International Network of Drug Dependence Treatment and Rehabilitation Resource Centres: Treatnet. Substance Abuse, 2010, 31, 251-263.	2.3	17
90	The management of opioid withdrawal. Drug and Alcohol Review, 2000, 19, 309-318.	2.1	15

#	ARTICLE	IF	CITATIONS
91	Overdose Among Heroin Users: Evaluation of an Intervention in South Australia. <i>Addiction Research and Theory</i> , 2001, 9, 481-501.	1.9	15
92	Maintenance Pharmacotherapy for Opioid Dependence and SF-36 Health Status: A Comparison With General Population Norms and Other Chronic Disorders. <i>Addictive Disorders and Their Treatment</i> , 2006, 5, 155-164.	0.5	15
93	Diversion and injection of buprenorphine-naloxone film two years post-introduction in Australia. <i>Drug and Alcohol Review</i> , 2016, 35, 83-91.	2.1	15
94	Identifying substance misuse in primary care: TAPS Tool compared to the WHO ASSIST. <i>Journal of Substance Abuse Treatment</i> , 2017, 76, 69-76.	2.8	15
95	The contribution of methamphetamine use to crime: Evidence from Australian longitudinal data. <i>Drug and Alcohol Dependence</i> , 2020, 216, 108262.	3.2	15
96	Injecting behaviour and risky needle use amongst methadone maintenance clients. <i>Drug and Alcohol Dependence</i> , 1994, 34, 113-119.	3.2	14
97	A latent class analysis of self-reported clinical indicators of psychosocial stability and adherence among opioid substitution therapy patients: Do stable patients receive more unsupervised doses?. <i>Drug and Alcohol Dependence</i> , 2014, 142, 46-55.	3.2	14
98	Outcomes of compulsory detention compared to community-based voluntary methadone maintenance treatment in Vietnam. <i>Journal of Substance Abuse Treatment</i> , 2018, 87, 9-15.	2.8	14
99	The effect of person, treatment and prescriber characteristics on retention in opioid agonist treatment: a 15-year retrospective cohort study. <i>Addiction</i> , 2021, 116, 3139-3152.	3.3	14
100	Revision of the Australian guidelines to reduce health risks from drinking alcohol. <i>Medical Journal of Australia</i> , 2021, 215, 518-524.	1.7	13
101	Harm Minimization in a Prohibition Context—Australia. <i>Annals of the American Academy of Political and Social Science</i> , 2002, 582, 80-93.	1.6	12
102	Correlates of retention on the South Australian Methadone Program 1981-91. <i>Australian and New Zealand Journal of Public Health</i> , 1998, 22, 771-776.	1.8	11
103	Antagonist-precipitated heroin withdrawal under anaesthetic prior to maintenance naltrexone treatment: determinants of withdrawal severity. <i>Drug and Alcohol Review</i> , 2003, 22, 425-431.	2.1	11
104	Ensuring the safety of new medications and devices: are naltrexone implants safe?. <i>Medical Journal of Australia</i> , 2008, 188, 438-439.	1.7	11
105	Same-day use of opioids and other central nervous system depressants amongst people who tamper with pharmaceutical opioids: A retrospective 7-day diary study. <i>Drug and Alcohol Dependence</i> , 2016, 166, 125-133.	3.2	11
106	Analysis of qualitative data from the investigation study in pregnancy of the ASSIST Version 3.0 (the Tj ETQq0 0 0 ggBT /Overlock 10 Tf	2.3	11
107	Feasibility of Studying a Brief Intervention to Help Chinese Villagers with Problem Alcohol Use After an Earthquake. <i>Alcohol and Alcoholism</i> , 2017, 52, 472-476.	1.6	11
108	LiMA: a study protocol for a randomised, double-blind, placebo controlled trial of lisdexamfetamine for the treatment of methamphetamine dependence. <i>BMJ Open</i> , 2018, 8, e020723.	1.9	11

#	ARTICLE	IF	CITATIONS
109	HIV in injecting drug users in Asian countries. <i>BMJ: British Medical Journal</i> , 2004, 329, 697-698.	2.3	10
110	Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. , 2006, , CD002022.		10
111	Methamphetamine Psychosis in Australia, Philippines, and Thailand. <i>Addictive Disorders and Their Treatment</i> , 2010, 9, 143-149.	0.5	10
112	Jurisdictional differences in opioid use, other licit and illicit drug use, and harms associated with substance use among people who tamper with pharmaceutical opioids. <i>Drug and Alcohol Review</i> , 2015, 34, 611-622.	2.1	10
113	Data Resource Profile: The Opioid Agonist Treatment and Safety (OATS) Study, New South Wales, Australia. <i>International Journal of Epidemiology</i> , 2021, 49, 1774-1775.	1.9	10
114	Retention of opioid agonist treatment prescribers across New South Wales, Australia, 2001â€“2018: Implications for treatment systems and potential impact on client outcomes. <i>Drug and Alcohol Dependence</i> , 2021, 219, 108464.	3.2	10
115	Risk of transmission of the human immunodeficiency virus in the prison setting. <i>Medical Journal of Australia</i> , 1989, 150, 722-722.	1.7	10
116	Opioid antagonists with minimal sedation for opioid withdrawal. , 2006, , CD002021.		9
117	Abstinence-orientated buprenorphine replacement therapy for young adults in out-patient counselling. <i>Drug and Alcohol Review</i> , 2006, 25, 123-130.	2.1	9
118	Investigation of the Alcohol, Smoking, and Substance Involvement Screening Test (the ASSIST) Version 3.0 in Pregnancy. <i>Addictive Disorders and Their Treatment</i> , 2013, 12, 123-135.	0.5	9
119	Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study. <i>BMJ Open</i> , 2020, 10, e034389.	1.9	9
120	The introduction of buprenorphine-naloxone film in opioid substitution therapy in Australia: Uptake and issues arising from changing buprenorphine formulations. <i>Drug and Alcohol Review</i> , 2015, 34, 603-610.	2.1	8
121	Latent Psychotic Symptom Profiles Amongst People Who Use Methamphetamine: What Do They Tell Us About Existing Diagnostic Categories?. <i>Frontiers in Psychiatry</i> , 2018, 9, 578.	2.6	8
122	A randomised controlled trial of a brief intervention for illicit drug use linked to ASSIST screening in a primary healthcare setting: results from the Australian component of the World Health Organization Phase III ASSIST studies. <i>Australian Journal of Primary Health</i> , 2018, 24, 149.	0.9	8
123	A clinical research priority setting study for issues related to the use of methamphetamine and emerging drugs of concern in Australia. <i>Drug and Alcohol Review</i> , 2022, 41, 309-319.	2.1	8
124	Hepatitis C and the history of injecting drug use in South Australia. <i>Medical Journal of Australia</i> , 1994, 161, 286-286.	1.7	7
125	Examining the cost and impact of dosing fees among clients in opioid agonist treatment: Results from a cross-sectional survey of Australian treatment clients. <i>Drug and Alcohol Review</i> , 2022, 41, 841-850.	2.1	7
126	The impact of opioid agonist treatment on fatal and non-fatal drug overdose among people with a history of opioid dependence in NSW, Australia, 2001â€“2018: Findings from the OATS retrospective linkage study. <i>Drug and Alcohol Dependence</i> , 2022, 236, 109464.	3.2	7



#	ARTICLE	IF	CITATIONS
127	Accidental drug toxicity associated with methadone maintenance treatment. Medical Journal of Australia, 1999, 170, 100-101.	1.7	6
128	The first methadone clinic in Beijing. Drug and Alcohol Review, 2005, 24, 285-287.	2.1	6
129	Injecting buprenorphineâ€naloxone film: Findings from an explorative qualitative study. Drug and Alcohol Review, 2015, 34, 623-629.	2.1	6
130	The prescription of methadone for opiate dependence in Australia, 1985â€1991. Medical Journal of Australia, 1993, 159, 107-108.	1.7	6
131	Systematic review processes and the management of opioid withdrawal. Australian and New Zealand Journal of Public Health, 2000, 24, 427-431.	1.8	5
132	Quality of life as a predictor of time to heroin relapse among male residents following release from compulsory rehabilitation centres in Vietnam. Drug and Alcohol Review, 2021, 40, 296-306.	2.1	5
133	Hospitalisations for non-fatal overdose among people with a history of opioid dependence in New South Wales, Australia, 2001â€2018: Findings from the OATS retrospective cohort study. Drug and Alcohol Dependence, 2021, 218, 108354.	3.2	5
134	Laws applying to minor cannabis offences in Australia and their evaluation. International Journal of Drug Policy, 1999, 10, 299-303.	3.3	4
135	A Training, Authorisation and Review Process for Methadone Prescribers. Journal of Maintenance in the Addictions, 2000, 1, 15-25.	0.1	4
136	A typology of people who tamper with pharmaceutical opioids: responses to introduction of a tamperâ€resistant formulation of controlledâ€release oxycodone. Pharmacoepidemiology and Drug Safety, 2015, 24, 1321-1333.	1.9	4
137	HIV infection among injecting drug users in the South Australian methadone program. Medical Journal of Australia, 1995, 162, 242-244.	1.7	4
138	In-patient treatment for the alcohol-dependent person: a public health perspective. Drug and Alcohol Review, 1994, 13, 195-202.	2.1	3
139	Therapeutic use of cannabis: clarifying the debate. Drug and Alcohol Review, 1998, 17, 445-452.	2.1	3
140	Substance use and treatment options in Cambodia. Drug and Alcohol Review, 2004, 23, 365-367.	2.1	3
141	Ethical considerations when researching with pregnant substance users and implications for practice. Addictive Behaviors, 2016, 60, 242-243.	3.0	3
142	Perceptions of injectable opioid agonist treatment (iOAT) among people who regularly use opioids in Australia: findings from a crossâ€sectional study in three Australian cities. Addiction, 2021, 116, 1482-1494.	3.3	3
143	Harm Minimization in a Prohibition Contextâ€Australia. Annals of the American Academy of Political and Social Science, 2002, 582, 80-93.	1.6	3
144	Amphetamines in Asia: the value of information networks. Drug and Alcohol Review, 2004, 23, 235-237.	2.1	2

#	ARTICLE	IF	CITATIONS
145	Improving outcomes in the treatment of opioid dependence (IOTOD): reflections on the impact of a medical education initiative on healthcare professionals' attitudes and clinical practice. <i>Journal of European CME</i> , 2018, 7, 1506197.	1.6	2
146	"The Drug Survey App": a protocol for developing and validating an interactive population survey tool for drug use among Aboriginal and Torres Strait Islander Australians. <i>Addiction Science &amp; Clinical Practice</i> , 2022, 17, 17.	2.6	2
147	Risk of transmission of the human immunodeficiency virus in the prison setting. <i>Medical Journal of Australia</i> , 1990, 153, 434-434.	1.7	1
148	Cochrane drugs and alcohol group: the development of systematic reviews of treatment outcome. <i>Alcohol and Alcoholism</i> , 2001, 36, 109-111.	1.6	1
149	Comment on: Doverty et al., Hyperalgesic responses in methadone maintenance patients ( <i>Pain</i> ) Tj ETQq1 1 0.784314 rgBT /Qverlock 10	4.2	1
150	PREVENTING HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION AMONG PRISONERS: PRISONERS' AND PRISON OFFICERS' KNOWLEDGE OF HIV AND THEIR ATTITUDES TO OPTIONS FOR PREVENTION. <i>Community Health Studies</i> , 1990, 14, 61-64.	0.0	1
151	The Ultrarapid Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST-Lite) and Implications for Neuropathology. , 2016, , 649-659.		1
152	Strengthening advocacy efforts with empirical evidence: A case example of the conduct, uptake and utilisation of research in drug policy decision-making in Vietnam. <i>International Journal of Drug Policy</i> , 2017, 49, 41-47.	3.3	1
153	End compulsory drug treatment in the Asia-Pacific region. <i>Lancet, The</i> , 2022, 399, 419-421.	13.7	1
154	Which substitution pharmacotherapy is most effective in treating opioid dependence?. <i>Medical Journal of Australia</i> , 2002, 176, 493-494.	1.7	0
155	Asia Pacific Column. <i>Drug and Alcohol Review</i> , 2004, 23, 133-134.	2.1	0
156	Mood Disturbance and Withdrawal Severity in Substitution Treatment for Opioid Dependence. <i>Addictive Disorders and Their Treatment</i> , 2010, 9, 1-7.	0.5	0
157	Screening for use of alcohol, tobacco and cannabis in pregnancy using self-report tools. <i>Journal of Developmental Origins of Health and Disease</i> , 2012, 3, 216-223.	1.4	0
158	Brief Intervention for Illicit Drug Users. , 2015, , 293-312.		0
159	Participant perspectives on the Australian WHO ASSIST Phase III brief intervention for illicit drug use in a primary healthcare setting. <i>Australian Journal of Primary Health</i> , 2018, 24, 518.	0.9	0
160	Response to commentaries. <i>Addiction</i> , 2019, 114, 1357-1358.	3.3	0
161	Heroin overdose: Responding to the epidemic. <i>Australian and New Zealand Journal of Psychiatry</i> , 2000, 34, A1-A2.	2.3	0
162	HIV in injecting drug users in Asian countries: Authors' reply. <i>BMJ: British Medical Journal</i> , 2005, 330, 147.2.	2.3	0

#	ARTICLE	IF	CITATIONS
163	Regulation and Decriminalisation of Illegal Substances in Thailand. Journal of Health Science and Medical Research, 0, , .	0.1	0
164	Brief Intervention for Illicit Drug Use. , 2021, , 655-671.		0